Search results for "Clostridium Infections"

showing 7 items of 7 documents

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

An emergent infectious disease: Clostridioides difficile infection hospitalizations, 10-year trend in Sicily

2021

Abstract Background Clostridioides difficile is the most common cause of healthcare-associated diarrhoea worldwide and C. difficile infection is an emerging infectious disease. In the US, its rates are monitored trough an active surveillance system, but many European Union member states still lack this, and in Italy no epidemiological data on C. difficile infection are available except for a few single-centre data. Aim To provide data on the C. difficile infection incidence in Sicily (the biggest and 5th most populous region of Italy) during a 10-year period. Methods We revised all the regional standardized discharge forms between 2009 and June 2019 using the code ICD-9 00845 of the Interna…

AdultMaleMicrobiology (medical)medicine.medical_specialtyPediatricsHealth care-associated diarrhoeaDiseaseCommunicable DiseasesClostridioidesEpidemiologyCase fatality ratemedicineHumansmedia_common.cataloged_instanceEuropean unionSicilyAgedmedia_commonCross InfectionOriginal PaperClostridioides difficilebusiness.industryIncidence (epidemiology)CorrectionGeneral Medicinemedicine.diseaseHospitalizationPneumoniaSurveillance of C. difficile.Infectious DiseasesClostridioides difficile infectionInfectious disease (medical specialty)Clostridium InfectionsEmerging infectious diseaseFemaleSurveillance of C. difficilebusinessInfection
researchProduct

Digestive disorders and Intestinal microbiota

2018

In the last decade, a barge body of scientific literature has suggested that specific alterations of the gut microbiota may be associated with ther development and clinical course of several gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, celiac disease, gastrointestinal cancer and Clostridium difficile infection. These alterations are often referred to as “dysbiosis”, a generic term designing reduction of gut microbiota biodiversity and alterations in its composition. Here, we provide a synthetic overview of the key concepts on the relationship between intestinal microbiota and gastrointestinal diseases, focusing on the translation of these concep…

Clostridioides difficileDigestive System DiseasesLiver DiseasesIBDmicrobiomeReviewdysbiosisClostridium difficileBiodiversityDigestive System NeoplasmsInflammatory Bowel Diseasesdigestive systemGastrointestinal MicrobiomeEndotoxinsIrritable Bowel SyndromeCeliac DiseaseIntestinal AbsorptionClostridium InfectionsHumansDisease SusceptibilityActa bio-medica : Atenei Parmensis
researchProduct

Clostridium baratii bacteremia associated with Kawasaki syndrome. First case report

2007

We experienced a case of a 3-year-old boy who presented signs and symptoms of Kawasaki syndrome. Two blood culture sets were processed by the hospital microbiology laboratory using a standard blood culturing system. The anaerobic bottles gave a positive result at day 3 after inoculation. The biochemical profiles produced by the RapID ANA II System showed that the organism was Clostridium baratii with a probability of 99%. Our case highlights the importance of C. baratii as a potential human pathogen and reports the associations with manifestations, which, to our knowledge, have not been previously described concomitantly with a clostridial infection.

ClostridiumMaleBOTULISM TYPE-F; DISEASE; ADULT; INFECTIONS; HATHEWAYI; TOXINBacteremiaTOXINMucocutaneous Lymph Node SyndromeDISEASEAgarBOTULISM TYPE-FADULTINFECTIONSChild PreschoolHATHEWAYIClostridium InfectionsHumansAnaerobiosisReagent Kits Diagnostic
researchProduct

Clostridium difficile heterogeneously impacts intestinal community architecture but drives stable metabolome responses

2015

Clostridium difficile-associated diarrhoea (CDAD) is caused by C. difficile toxins A and B and represents a serious emerging health problem. Yet, its progression and functional consequences are unclear. We hypothesised that C. difficile can drive major measurable metabolic changes in the gut microbiota and that a relationship with the production or absence of toxins may be established. We tested this hypothesis by performing metabolic profiling on the gut microbiota of patients with C. difficile that produced (n=6) or did not produce (n=4) toxins and on non-colonised control patients (n=6), all of whom were experiencing diarrhoea. We report a statistically significant separation (P-value o0…

DiarrheaMaleBacterial ToxinsDiseasePathogenesisGut floraMicrobiologyMicrobiologyFecesClostridiumMetabolomicsRNA Ribosomal 16SmedicineMetabolomeHumansMetabolomicsColitisEcology Evolution Behavior and SystematicsbiologyClostridioides difficileClostridium difficilebiology.organism_classificationmedicine.diseaseColitisIntestinesRNA BacterialDiarrheaClostridium InfectionsMetabolomeFemaleOriginal Articlemedicine.symptomBacterial infection
researchProduct

Rapid growth predisposes broilers to necrotic enteritis

2019

Over the past 50 years, intentional genetic selection within the broiler industry has led to major improvements in both body weight gain (BWG) and feed conversion efficiency. Next to its economic advantages, enhancing BWG can increase the risk of metabolic and skeletal disorders. The aim of this study was to examine whether higher BWG is a predisposing factor for broiler necrotic enteritis. In this study, 300 broilers were challenged with Clostridium perfringens using a well-established, previously described challenge model. It was found that birds with higher body weight (BW) and BWG before challenge were predisposed to develop more severe necrotic enteritis lesions. After challenge, the a…

MaleVeterinary medicinebakteeritaudit040301 veterinary sciencesClostridium perfringensbody weight gainBiologyBody weightmedicine.disease_causeWeight Gainnecrotic enteritisbroilerFeed conversion ratiopainonnousu0403 veterinary scienceNecrosisFood AnimalsRisk FactorsmedicineAnimalsPoultry DiseasesNecrotic enteritispredisposing factoralttiusGeneral Immunology and Microbiologytulehdus0402 animal and dairy scienceBroilereläintaudit04 agricultural and veterinary sciencesClostridium perfringens040201 dairy & animal scienceEnteritisClostridium InfectionsGenetic selectionAnimal Science and ZoologyFemalegrowth rateDisease SusceptibilityChickensbroilerit
researchProduct

Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of …

2017

Summary Background Patients admitted to hospital can acquire multidrug-resistant organisms and Clostridium difficile from inadequately disinfected environmental surfaces. We determined the effect of three enhanced strategies for terminal room disinfection (disinfection of a room between occupying patients) on acquisition and infection due to meticillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, C difficile , and multidrug-resistant Acinetobacter . Methods We did a pragmatic, cluster-randomised, crossover trial at nine hospitals in the southeastern USA. Rooms from which a patient with infection or colonisation with a target organism was discharged were terminally dis…

Malemedicine.medical_specialtyLetterSodium HypochloriteUltraviolet RaysDisinfectantPopulationDrug resistance030501 epidemiologyMicrobiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug Resistance Multiple BacterialSepsisPatients' RoomsMedicineHumans030212 general & internal medicineeducationeducation.field_of_studyCross InfectionCross-Over Studiesbusiness.industryClostridioides difficileMultidrug resistant organismsIncidence (epidemiology)General MedicineClostridium difficileMiddle AgedCrossover studyUnited StatesTerminal cleaningDisinfectionQuaternary Ammonium CompoundschemistrySodium hypochloriteRelative riskClostridium InfectionsFemale0305 other medical sciencebusinessICU-acquired infectionsDisinfectantsLancet (London, England)
researchProduct